Clinical Trials on Endometrioid Endometrial Cancer in United States

Total 24169 results

National Cancer Institute (NCI)

Active, not recruiting

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Atypical Hyperplasia

United States
Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium | Neoplasms, Endometrial

United States
Mayo Clinic

Not yet recruiting

Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Stage IA Uterine Corpus Cancer AJCC v8 | Stage IB Uterine Corpus Cancer AJCC v8

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
Women and Infants Hospital of Rhode Island

Unknown

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

Grade 1 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Complex Atypical Endometrial Hyperplasia

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous...

United States
M.D. Anderson Cancer Center

Recruiting

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Recurrent Endometrial Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Refractory Endometrial Carcinoma | Refractory... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (LEVER)

Atypical Endometrial Hyperplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

United States
Aadi Bioscience, Inc.

Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Cancer | Endometrial Cancer | Tumor | Recurrent Endometrial Carcinoma | Endometrioid Endometrial Cancer | Endometrioid Tumor

United States
HonorHealth Research Institute
Merck Sharp & Dohme LLC; Salarius Pharmaceuticals, LLC

Withdrawn

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Ovarian Endometrioid Adenocarcinoma | Endometrial Cancer | SCCOHT | Ovarian Clear Cell Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Thomas Jefferson University
Context Therapeutics Inc.

Active, not recruiting

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Refractory Endometrial Carcinoma | Refractory Endometrial Endometrioid Adenocarcinoma | Refractory Endometrial Adenocarcinoma | Refractory Endometrial Clear Cell Adenocarcinoma | Refractory Endometrial Mixed Cell Adenocarcinoma | Refractory Endometrial Serous Adenocarcinoma | Refractory Endometrial...

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)

Suspended

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Endometrial Cancer | Endometrial Carcinoma | Cancer of Endometrium | Carcinoma of Endometrium

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma

United States
GOG Foundation
Novartis

Recruiting

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Endometroid Endometrial Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
Onconova Therapeutics, Inc.

Recruiting

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Endometrioid Endometrial Cancer

United States
Washington University School of Medicine
ScaleDown

Completed

Scale Down for Endometrial Cancer

Endometrial Cancer | Cancer of the Endometrium

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
University of Utah

Recruiting

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (SAVE)

Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Sarcoma | Uterine Corpus Carcinosarcoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Endometrial Cancer | Endometrioid Adenocarcinoma | Endometrial Cancer Stage I

United States, Czechia, Italy, Norway
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
Massachusetts General Hospital

Withdrawn

PET/MRI in Endometrial Cancer

Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Cytoreductive Surgery | High Grade Serous Carcinoma | Grade 3 Endometrial Endometrioid Adenocarcinoma

United States
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...

United States
University of Oklahoma

Withdrawn

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

Endometrioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Endometrial Adenosquamous... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC... and other conditions

United States
Duke University

Completed

Adaptive Pet Study

Head and Neck Cancers | Lung and Esophagus Cancers | Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
Duke University
Wallace H. Coulter Foundation

Completed

Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy

Cancer of the Cervix, Cancer of the Endometrium

United States
Washington University School of Medicine
Tesaro, Inc.

Recruiting

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Endometrial Cancer | Cancer of the Endometrium

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Grade 3 Endometrial Endometrioid Adenocarcinoma | Malignant Mixed Mesodermal (Mullerian) Tumor

United States
Queensland Centre for Gynaecological Cancer
National Health and Medical Research Council, Australia; Johnson & Johnson... and other collaborators

Completed

Laparoscopic Approach to Cancer of the Endometrium

Endometrial Cancer

United Kingdom, Australia, Hong Kong, New Zealand
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
Sutro Biopharma, Inc.

Recruiting

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Ovarian Carcinoma | Endometrioid Adenocarcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States, Spain
National Cancer Institute (NCI)
Mayo Clinic

Completed

Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

Endometrial Cancer | Gynecological Cancers

United States
M.D. Anderson Cancer Center
National Comprehensive Cancer Network

Recruiting

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Metastatic Cancer | Endometrial Carcinoma | Endometrium Cancer

United States
Saad Amer
University Hospitals of Derby and Burton NHS Foundation Trust

Unknown

The Impact of Surgical Treatment of Endometriomas on Ovarian Reserve

Endometriosis

United Kingdom
Memorial Sloan Kettering Cancer Center
Context Therapeutics Inc.

Active, not recruiting

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Granulosa Cell Ovarian Cancer | Low Grade Serous Ovarian/ Primary Peritoneal Cancer | Endometrioid Endometrial Cancer

United States
Duke University
Duke Cancer Institute

Completed

Endometrial Cancer Diet and Exercise

Early Stage Endometrial Cancer

United States
Masonic Cancer Center, University of Minnesota

Completed

Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study

Cervical Cancer | Ovarian Cancer | Uterine Endometrial Cancer

United States
Wake Forest University Health Sciences

Withdrawn

SIRT-1 Antagonism for Endometrial Receptivity (SAFER)

Uterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, Nonimplantation

United States

Clinical Trials on Endometrioid Endometrial Cancer in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations